Postmortem toxicology findings from the Camden Opioid Research Initiative.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
02
2023
accepted:
26
09
2023
medline:
3
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
The United States continues to be impacted by decades of an opioid misuse epidemic, worsened by the COVID-19 pandemic and by the growing prevalence of highly potent synthetic opioids (HPSO) such as fentanyl. In instances of a toxicity event, first-response administration of reversal medications such as naloxone can be insufficient to fully counteract the effects of HPSO, particularly when there is co-occurring substance use. In an effort to characterize and study this multi-faceted problem, the Camden Opioid Research Initiative (CORI) has been formed. The CORI study has collected and analyzed post-mortem toxicology data from 42 cases of decedents who expired from opioid-related toxicity in the South New Jersey region to characterize substance use profiles. Co-occurring substance use, whether by intent or through possible contamination of the illicit opioid supply, is pervasive among deaths due to opioid toxicity, and evidence of medication-assisted treatment is scarce. Nearly all (98%) of the toxicology cases show the presence of the HPSO, fentanyl, and very few (7%) results detected evidence of medication-assisted treatment for opioid use disorder, such as buprenorphine or methadone, at the time of death. The opioid toxicity reversal drug, naloxone, was detected in 19% of cases, but 100% of cases expressed one or more stimulants, and sedatives including xylazine were detected in 48% of cases. These results showing complex substance use profiles indicate that efforts at mitigating the opioid misuse epidemic must address the complications presented by co-occurring stimulant and other substance use, and reduce barriers to and stigmas of seeking effective medication-assisted treatments.
Identifiants
pubmed: 37910493
doi: 10.1371/journal.pone.0292674
pii: PONE-D-23-05390
pmc: PMC10619848
doi:
Substances chimiques
Analgesics, Opioid
0
Fentanyl
UF599785JZ
Naloxone
36B82AMQ7N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0292674Informations de copyright
Copyright: © 2023 Kusic et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Neuropsychiatr Dis Treat. 2017 May 24;13:1399-1408
pubmed: 28579787
BMC Med Genomics. 2021 Jan 7;14(1):16
pubmed: 33413350
Am J Drug Alcohol Abuse. 2019;45(1):1-10
pubmed: 30675818
J Subst Abuse Treat. 2020 Feb;109:80-85
pubmed: 31810594
Am J Addict. 2020 Jul;29(4):345-348
pubmed: 32167629
JMIR Public Health Surveill. 2021 May 27;7(5):e29298
pubmed: 33999828
J Anal Toxicol. 2017 Apr 1;41(3):242-249
pubmed: 28096302
Clin Chim Acta. 2021 Oct;521:151-154
pubmed: 34265257
Int J Drug Policy. 2019 Aug;70:40-46
pubmed: 31079029
J Forensic Leg Med. 2019 Feb;61:128-140
pubmed: 30621882
Biol Psychiatry. 2020 Jan 1;87(1):82-88
pubmed: 31420089
Addict Sci Clin Pract. 2022 Sep 4;17(1):47
pubmed: 36057608
Can J Anaesth. 2008 Aug;55(8):521-5
pubmed: 18676387
J Anal Toxicol. 2022 Oct 14;46(8):911-917
pubmed: 35770859
BMC Health Serv Res. 2019 Jul 2;19(1):440
pubmed: 31266495
Public Health Rep. 2020 Jan;135(1):6-10
pubmed: 31738861
Addiction. 2021 Jan;116(1):96-104
pubmed: 32428386
MMWR Morb Mortal Wkly Rep. 2021 Feb 12;70(6):202-207
pubmed: 33571180
J Subst Abuse Treat. 2022 Sep;140:108828
pubmed: 35749919
CNS Drugs. 2019 Jun;33(6):567-580
pubmed: 31062259
J Pain Palliat Care Pharmacother. 2015 Sep;29(3):281-9
pubmed: 26375198
MMWR Morb Mortal Wkly Rep. 2014 Oct 3;63(39):849-54
pubmed: 25275328
Cancer Epidemiol Biomarkers Prev. 2020 Mar;29(3):650-658
pubmed: 31915141
NCHS Data Brief. 2021 Dec;(426):1-8
pubmed: 34978529
Cureus. 2022 May 30;14(5):e25477
pubmed: 35800815
Front Psychiatry. 2022 Jul 06;13:918197
pubmed: 35873238
Harm Reduct J. 2018 Jul 5;15(1):34
pubmed: 29976195
Ther Adv Drug Saf. 2018 Jan;9(1):63-88
pubmed: 29318006
Popul Health Manag. 2021 Feb;24(S1):S43-S51
pubmed: 33031013
MMWR Morb Mortal Wkly Rep. 2011 Nov 4;60(43):1487-92
pubmed: 22048730
Addiction. 2022 Dec;117(12):3079-3088
pubmed: 35652681
Subst Use Misuse. 2022;57(10):1511-1522
pubmed: 35815614
Am J Drug Alcohol Abuse. 2017 Mar;43(2):155-170
pubmed: 27589579
Ann Emerg Med. 2018 Jul;72(1):1-8.e1
pubmed: 29530654
Neuropsychopharmacology. 2019 Aug;44(9):1667-1673
pubmed: 30867551
Subst Abus. 2022;43(1):465-478
pubmed: 34228944
Int J Drug Policy. 2021 Jul;93:103169
pubmed: 33627302
J Med Toxicol. 2021 Jan;17(1):10-15
pubmed: 32648229
Addict Sci Clin Pract. 2022 Jun 2;17(1):30
pubmed: 35655293
Am J Drug Alcohol Abuse. 2018;44(6):595-603
pubmed: 29693427
Drug Alcohol Depend. 2022 Apr 1;233:109380
pubmed: 35247724
JAMA Netw Open. 2022 May 2;5(5):e2211363
pubmed: 35536575
Drug Deliv Transl Res. 2022 Feb;12(2):376-383
pubmed: 34817831
J Clin Psychiatry. 2022 Apr 27;83(3):
pubmed: 35485928
Addiction. 2018 Mar;113(3):484-493
pubmed: 29143400
Am J Public Health. 2020 Feb;110(2):244-250
pubmed: 31855487
Int J Environ Res Public Health. 2022 Jul 21;19(14):
pubmed: 35886734
JAMA. 2015 Apr 28;313(16):1636-44
pubmed: 25919527
Acad Forensic Pathol. 2017 Mar;7(1):19-35
pubmed: 31239953
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1136-1141
pubmed: 34437522
Am J Emerg Med. 2021 Feb;40:103-105
pubmed: 33360606
MMWR Morb Mortal Wkly Rep. 2017 Sep 01;66(34):897-903
pubmed: 28859052
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Drug Alcohol Depend. 2019 May 1;198:28-33
pubmed: 30877954
Forensic Sci Int. 2010 Jan 30;194(1-3):e17-9
pubmed: 19850423
Inj Prev. 2021 Aug;27(4):395-398
pubmed: 33536231
J Med Toxicol. 2022 Oct;18(4):267-296
pubmed: 36070069
Drug Alcohol Depend. 2019 Apr 1;197:78-82
pubmed: 30784952
Anal Chem. 2022 Sep 20;94(37):12706-12714
pubmed: 36082424
J Addict Med. 2020 Mar/Apr;14(2S Suppl 1):1-91
pubmed: 32511106
Psychopharmacology (Berl). 2022 Jul;239(7):2063-2081
pubmed: 35385972
Subst Abuse. 2022 Jun 27;16:11782218221103859
pubmed: 35783464
Drug Alcohol Depend. 2019 Jul 1;200:59-63
pubmed: 31100636
Int J Drug Policy. 2019 Sep;71:157-163
pubmed: 30691944
Int J Drug Policy. 2022 Jul;105:103703
pubmed: 35561484
Front Psychiatry. 2021 Dec 07;12:778992
pubmed: 34950072
J Behav Health Serv Res. 2020 Oct;47(4):601-613
pubmed: 32495248
Fundam Clin Pharmacol. 2022 Apr;36(2):436-442
pubmed: 34837277
Drug Alcohol Depend. 2020 Sep 1;214:108147
pubmed: 32650192
JAMA Netw Open. 2022 Mar 1;5(3):e223821
pubmed: 35319762
Ann Emerg Med. 2023 Feb;81(2):165-175
pubmed: 36192278
J Neurosci Rural Pract. 2012 Jan;3(1):45-50
pubmed: 22346191
West J Med. 2000 Jan;172(1):11-4
pubmed: 10695434
Am Fam Physician. 2018 Mar 1;97(5):313-320
pubmed: 29671504
Drug Alcohol Rev. 2021 Feb;40(2):281-286
pubmed: 32969097
Int J Drug Policy. 2021 Jan;87:102845
pubmed: 33246303